CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

Respiratory Syncytial Virus and Associations With Cardiovascular Disease in Adults Randomized Comparison Between Radial and Femoral Large-Bore Access for Complex Percutaneous Coronary Intervention Radionuclide Image-Guided Repair of the Heart Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone Association of Prior Left Ventricular Ejection Fraction With Clinical Outcomes in Patients With Heart Failure With Midrange Ejection Fraction Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC The spectrum of chronic coronary syndromes: genetics, imaging, and management after PCI and CABG

Review ArticleVolume 71, Issue 14, April 2018

JOURNAL:J Am Coll Cardio. Article Link

Respiratory Syncytial Virus and Associations With Cardiovascular Disease in Adults

KS Ivey, KM Edwards, HK Talbot et al. Keywords: cardiac exacerbation; hospitalizations; respiratory syncytial virus

ABSTRACT


Respiratory syncytial virus (RSV) is historically known for causing respiratory illness in young children, but the appreciation of its impact on older adults is growing. Studies have shown that hospitalization for respiratory illness due to RSV is complicated by cardiovascular events in 14% to 22% of adult patients, including worsening congestive heart failure, acute coronary syndrome, and arrhythmias. Additionally, underlying cardiovascular disease is associated with hospitalization in 45% to 63% of adults with confirmed RSV. In summary, patients with cardiopulmonary disease have higher rates of health care utilization for RSV-related illness and worse outcomes. Patients with cardiovascular disease likely represent an important target population for the rapidly developing field of RSV vaccines.